News

Article

Mass Spec Software Optimizes Biopharmaceutical Characterization

Agilent Technologies Inc. introduced the MassHunter BioConfirm application, which allows users to rapidly create targeted screening methods.

Agilent Technologies Inc. introduced the MassHunter BioConfirm application, which allows users to rapidly create targeted screening methods to characterize intact proteins and biosimilars for biopharmaceutical research, the company reports.

MassHunter BioConfirm software provides mirror plots for the comparison of biosimilars and peak modeling deconvolution to determine the molecular weight of intact proteins. The peak-modeling algorithm removes artifacts from a mass spectrum and helps resolve overlapped peaks. The resulting (simplified) spectra then allow researchers to visualize the precision of the mass measurement and ensure the accuracy of their results. This enables rapid confirmation of intact protein sequences and modifications.

Agilent’s MassHunter Workstation portfolio includes 20 individual software applications designed to optimize instrument control, data acquisition and qualitative/quantitative data analysis for Agilent’s time-of-flight, quadrupole time-of-flight, triple quadrupole, and inductively coupled plasma mass spectrometry systems.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content